Nexpring Health

🚨 BIG NEWS 🚨​​
The Nexpring Health booth just got a whole lot more exciting! Join the conversation with Irene Cuerva-Sáiz, MSc​ at our in-booth Vitrification and Media Workshop. With extensive experience in IVF laboratory practice, numerous scientific publications, and hands-on expertise using both culture media and vitrification technologies, Irene brings a wealth of practical and scientific knowledge to the conversation.​

Space will be limited… be sure to catch it live 👇​​
👤 Irene Cuerva-Sáiz, MSc​
📅 Monday, 6 July​
⏰ 1300-1400​
📍 Booth C12 ​

Irene Cuerva-Sáiz, MSc is the Director of the Embryology laboratory of the Hospital General Universitario of Valencia.​
No sign-up required.​

The science has supported lower lactate culture media for decades. So why did the field standardize around 5 mM?
Find out in this Nexpert Webinar with Lindsey VerMilyea, “True continuous culture from Day 0: Application of a low lactate embryo culture system to improve IVF outcomes”.

Join the webinar on Monday, June 22
Presentation Time: 2pm EST / 7pm CET
Live Q&A with our Nexpert Panel Time: 2pm EST / 7pm CET

Registration link in comments.
Don’t want to wait? Contact your Nexpring Health Sales Rep for exclusive early access.

In this session, you’ll learn:
✴️ How elevated lactate levels suppress embryo metabolism by reducing NAD⁺ availability and limiting ATP production
✴️ The research behind low lactate culture and why it’s gaining renewed attention
✴️ Clinical data across maturation, fertilization, blastulation, euploidy, and ongoing pregnancy rates
✴️ Why timing matters, including the case for introducing low lactate as early as possible
✴️ Practical considerations for implementing low lactate protocols in your lab
✴️ Whether you’re evaluating new culture media or optimizing your current approach, you’ll gain the scientific and clinical context needed to make informed decisions.

Presented by Lindsey VerMilyea, Senior Clinical Research Coordinator at Nexpring Health and a clinical embryologist for 20 years.
Nexpert Panel: Antonio Alcaide Raya, Kathrin Buchanan, TS (ABB), CLSp(RB), Brad Zavy, MSc, TS (ABB)
Webinar Host: Caleigh Findley, PhD

Every microtool and pipette plays a role in an IVF procedure.

With ART-focused manufacturing in Pennsylvania, Belgium, and the Czech Republic, our portfolio is built to support quality, consistency, and patient outcomes.

Because when every detail matters, dependable tools make the difference.
✴️ Explore our trusted, comprehensive solutions: https://nexpringhealth.com/insights/insight/microtools-and-pipettes-rebuilt-advancing-art-manufacturing-for-consistency-and-confidence/

The right conditions change everything.�

In 1984, Planer was recognized with the Queen’s Award for Technological Achievement for our pioneering work in controlled-rate freezing. That same year, our technology played a critical role in a global milestone: the birth of the first human baby from a frozen embryo in Melbourne, Australia. Zoe Leyland’s mother had 11 embryos frozen in a Planer Controlled Rate Freezer which was developed by Planer and Professor David Pegg.�

Today, Planer’s systems are the global standard in biobanking, supporting the preservation of stem cells, tissue, and other critical biological materials. Because true innovation doesn’t just advance science – it changes lives.

Stable outcomes, even through change.

Allison Davis, MS, TS (ABB), Lab Manager at Ovation Indianapolis, conducted a real-world retrospective review of 461 autologous FET cycles that found no detriment to outcomes after switching cryodevices with a fast warming protocol.

“Labs will have SOPs to follow when implementing new products or procedures, but there is no one single right way to accomplish change,” said Davis. “As long as you are careful and methodical with implementation, while tracking important KPIs and training, a successful transition can occur.”

See what it means for labs evaluating their next move.
https://nexpringhealth.com/insights/insight/stable-patient-outcomes-after-switching-cryodevices-with-a-fast-warming-protocol/

Expanding what’s possible, before birth.

Our community isn’t afraid to tackle complexity. Specialized innovations like the Harrison Fetal Bladder Stent help improve outcomes at every stage of the journey, even in rare cases.

This product was also the very first to receive a Humanitarian Device Exemption from the FDA, helping define the FDA’s HDE approval pathway.

The Harrison Fetal Bladder Stent from Cook enabled early, minimally invasive intervention for fetal conditions like lower urinary tract obstruction. By helping preserve organ function and support development in utero, it marked an important step forward in fetal therapy. Because every stage of the journey matters.

Watch the tape and know your stats for a clearer path forward. When it comes to building a family, clarity beats assumptions every time.

Most people think fertility testing starts and ends with a semen analysis.
It doesn’t. Today’s andrology tools go much deeper:
From standard semen analysis and hormone testing, to DNA fragmentation, to epigenetic insights, and even emerging AI-assisted s***m selection.
Each layer adds clarity. Each step leads to better decisions.

Thank you RESOLVE: The National Infertility Association for another National Infertility Awareness Week full of impact and action!



Game plan photo by Nguyen Thu Hoai on Unsplash

Fertility isn’t a guessing game.
If it matters, you check it.

According to the World Health Organization reference ranges, key semen parameters matter: motility (>40%), concentration (≥15 M/mL), and morphology (>4%). If you’re trying to conceive, or planning to, get tested. Knowledge isn’t uncomfortable, regret is.

RESOLVE: The National Infertility Association

---
American Urological Association/American Society for Reproductive Medicine guideline. Diagnosis and Treatment of Infertility in Men. AUA; updated 2024. WHO lower limits (≥15 million/mL, motility/ morphology cutoffs) guide clinical interpretation of semen parameters.